Analysts Set Dechra Pharmaceuticals plc (DPH) Price Target at $2,121.17
Dechra Pharmaceuticals plc (LON:DPH) has been assigned a consensus recommendation of “Buy” from the eight analysts that are currently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is GBX 2,121.17 ($29.31).
Several brokerages have recently commented on DPH. Numis Securities restated an “add” rating and set a GBX 2,640 ($36.47) price target on shares of Dechra Pharmaceuticals in a research note on Friday, February 2nd. Jefferies Group raised Dechra Pharmaceuticals to a “buy” rating and raised their price objective for the company from GBX 2,221 ($30.69) to GBX 2,631 ($36.35) in a research report on Tuesday, January 30th. Finally, Royal Bank of Canada downgraded Dechra Pharmaceuticals to a “sector performer” rating and raised their price objective for the company from GBX 2,200 ($30.40) to GBX 2,400 ($33.16) in a research report on Thursday, February 1st.
Shares of Dechra Pharmaceuticals (LON DPH) traded up GBX 6 ($0.08) during trading on Friday, hitting GBX 2,258 ($31.20). The stock had a trading volume of 199,846 shares, compared to its average volume of 200,367. The stock has a market capitalization of $2,230.00 and a price-to-earnings ratio of 8,064.29. Dechra Pharmaceuticals has a 1 year low of GBX 1,530 ($21.14) and a 1 year high of GBX 2,458 ($33.96).
Dechra Pharmaceuticals Company Profile
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.
Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.